Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant Chemotherapy.
Pardo JC, Sanhueza T, Ruiz de Porras V, Etxaniz O, Rodriguez H, Martinez-Cardús A, Grande E, Castellano D, Climent MA, Lobato T, Estudillo L, Jordà M, Carrato C, Font A. Pardo JC, et al. Among authors: castellano d. J Clin Med. 2022 Jan 19;11(3):497. doi: 10.3390/jcm11030497. J Clin Med. 2022. PMID: 35159947 Free PMC article.
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
Castellano D, del Muro XG, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, Pardo A, Guzmán C, Cerezo SD, Grande E. Castellano D, et al. Ann Oncol. 2009 Nov;20(11):1803-12. doi: 10.1093/annonc/mdp067. Epub 2009 Jun 23. Ann Oncol. 2009. PMID: 19549706 Free PMC article. Clinical Trial.
Advances in pancreatic neuroendocrine tumor treatment.
Castellano D, Grande E, Barriuso J. Castellano D, et al. N Engl J Med. 2011 May 12;364(19):1872-3; author reply 1873-4. doi: 10.1056/NEJMc1102746. N Engl J Med. 2011. PMID: 21561356 No abstract available.
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J, Leandro-García LJ, González Del Alba A, Morente M, Alemany I, Esteban E, Arranz JA, Climent MA, Gallardo E, Castellano DE, Bellmunt J, Mellado B, Puente J, Moreno F, Font A, Hernando S, Robledo M, Rodríguez-Antona C. Garcia-Donas J, et al. Among authors: castellano de. Ann Oncol. 2013 Sep;24(9):2409-14. doi: 10.1093/annonc/mdt219. Epub 2013 Jun 20. Ann Oncol. 2013. PMID: 23788753 Free article.
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma.
Prior C, Perez-Gracia JL, Garcia-Donas J, Rodriguez-Antona C, Guruceaga E, Esteban E, Suarez C, Castellano D, del Alba AG, Lozano MD, Carles J, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Gurpide A, Lopez-Picazo JM, Hernandez AG, Mellado B, Martínez E, Moreno F, Font A, Calvo A. Prior C, et al. Among authors: castellano d. PLoS One. 2014 Jan 24;9(1):e86263. doi: 10.1371/journal.pone.0086263. eCollection 2014. PLoS One. 2014. PMID: 24475095 Free PMC article.
Phase II clinical trial of PM00104 (Zalypsis(®)) in urothelial carcinoma patients progressing after first-line platinum-based regimen.
Castellano DE, Bellmunt J, Maroto JP, Font-Pous A, Morales-Barrera R, Ghanem I, Suarez C, Martín Lorente C, Etxaniz O, Capdevila L, Coronado C, Alfaro V, Siguero M, Fernández-Teruel C, Carles J. Castellano DE, et al. Cancer Chemother Pharmacol. 2014 Apr;73(4):857-67. doi: 10.1007/s00280-014-2419-7. Epub 2014 Feb 26. Cancer Chemother Pharmacol. 2014. PMID: 24570330 Clinical Trial.
334 results